[Pharmacological and clinical profiles of Fulvestrant (Faslodex(®)) in the treatment of advanced or recurrenced breast cancer].
S.Yano@astrazeneca.com
Seiichi
S
Yano
Seimin
S
Kamano
Toshiyasu
T
Sato
Lan
L
Chen
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D015536:Down-Regulation / Q000187:drug effects; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D051381:Rats; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D000077267:Fulvestrant; D004958:Estradiol